8-K: Alumis Inc. Stockholders Approve Merger with ACELYRIN, Inc.

Alumis Inc. stockholders voted to approve the merger with ACELYRIN, Inc. at a special meeting held on May 13, 2025.

Summary

• Alumis Inc. held a special meeting of stockholders on May 13, 2025, to vote on the proposed merger with ACELYRIN, Inc.
• The stockholders approved the issuance of Alumis stock to ACELYRIN stockholders in connection with the merger.
• The stockholders also approved the adjournment of the special meeting, if necessary, to solicit additional proxies.
• Approximately 88.98% of outstanding shares were represented at the meeting, with 42,021,905 shares of Company Common Stock voting.
• The merger is expected to close on May 21, 2025, subject to customary closing conditions.
• These conditions include the absence of any order or law preventing the merger, the listing of shares on the Nasdaq Global Select Market, and the SEC declaring the Form S-4 effective.

Sentiment

Score: 7

Explanation: The document conveys a positive sentiment as a key step in the merger process has been completed. However, the presence of forward-looking statements and associated risks tempers the overall optimism.

Positives

• Stockholder approval removes a key hurdle for the merger's completion.
• High stockholder representation (88.98%) indicates strong support for the transaction.

Risks

• The merger is still subject to customary closing conditions, including regulatory approvals and Nasdaq listing.
• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The merger between Alumis and ACELYRIN is expected to close on May 21, 2025, subject to customary closing conditions.

Industry Context

This merger reflects a trend of consolidation within the biotechnology industry, where companies combine to leverage resources and pipelines.

Comparison to Industry Standards

• Mergers in the biotech industry are common, with companies like Pfizer and Seagen recently merging for \$43 billion.
• The success of this merger will depend on the integration of Alumis' and ACELYRIN's pipelines and technologies, similar to how AbbVie integrated Allergan after their acquisition.

Stakeholder Impact

• Shareholders of Alumis will receive shares in the combined company.
• Employees of both companies may experience changes as a result of the merger.
• The combined entity may have a stronger market position, potentially benefiting customers.

Next Steps

• Fulfillment of customary closing conditions.
• Listing of shares of Company Common Stock issuable in connection with the Merger on the Nasdaq Global Select Market.
• Declaration of effectiveness by the Securities and Exchange Commission of a Form S-4 under the Securities Act of 1933, as amended, and no stop order suspending the effectiveness of the Form S-4 having been issued.

Key Dates

Keywords

merger, ACELYRIN, Alumis, stockholders, approval, issuance, shares